

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of **March, 2021**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IMV Inc.**

Date: March 1, 2021

By: /s/ Pierre Labbé  
Name: Pierre Labbé  
Title: Chief Financial Officer

---

Form 6-K Exhibit Index

**Exhibit  
Number**

**Document Description**

[99.1](#)

[News Release dated March 1, 2021. IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference](#)

---

**FOR IMMEDIATE RELEASE****IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference**

**Dartmouth, Nova Scotia; March 1, 2021** – IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team will be participating at the H.C. Wainwright Global Life Sciences Conference which will be held virtually on March 9-10.

**H.C. Wainwright Global Life Sciences Conference**

Presentation availability time: Tuesday, March 9, 2021 at 7:00 AM Eastern Time

A link to this presentation will be available under “[Events, Webcasts and Presentations](#)” in the investors section of IMV’s website at the above-mentioned time and for approximately 30 days thereafter.

**IMV Forward-Looking Statements**

*This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the FDA potentially granting accelerated regulatory approval of DPX-Survivac and the timing of expected results from other DPX-Survivac’s studies with other tumor types. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful design and completion of clinical trials and the receipt and timely receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).*

## About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer immunotherapies and vaccines against infectious diseases based on the Company's proprietary drug delivery platform, DPX. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Visit [www.imv-inc.com](http://www.imv-inc.com) and connect with us on [Twitter](#) and [LinkedIn](#).

###

## Source: IMV Inc.

### Investor Relations

#### Marc Jasmin, Senior Director, Investor Relations, IMV

O: (902) 492-1819, ext: 1042

M: (514) 617-9481 E: [mjasmin@imv-inc.com](mailto:mjasmin@imv-inc.com)

#### Irina Koffler, Managing Director, LifeSci Advisors

O: (646) 970-4681 M: (917) 734-7387

E: [ikoffler@lifesciadvisors.com](mailto:ikoffler@lifesciadvisors.com)

### Media

#### Delphine Davan, Director of Communications, IMV

M: (514) 968-1046

E: [ddavan@imv-inc.com](mailto:ddavan@imv-inc.com)

---